Abstract:Ademetionine 1,4-Butanedisulfonate (SAMe) is widely used as a prescription drug to treat cholestasis associated with liver disease, and is also used to treat depression, Alzheimer's disease and other diseases. Currently, the main way to produce SAMe is by fermentation of S-adenosylmethionine synthetase（SAMS）. However, during the fermentation process, host cells produce contaminants unrelated to the treatment. Among them, host cell protein (HCP), which is co-purified with the drug, is the main impurity in the production process. HCP-induced antigenic reactions can lead to allergies or other adverse reactions and affect drug quality, efficacy, and safety. Enzyme-linked immunosorbent assay (ELISA) and mass spectrometry (MS) are currently used as the main analytical methods for measuring HCP. The ELISA method may ignore some HCPs with low immunogenicity, while mass spectrometry is primarily employed for the characterization of proteomes. Orthogonal methods can more effectively evaluate impurities in drugs. In this study, ELISA was initially utilized to quantify the content of Saccharomyces cerevisiae host protein in 11 batches of SAMe active pharmaceutical ingredient (API) from two suppliers, then the above APIs were qualitatively analyzed by MS method. Following the identification of surrogate peptide of SAMS, an Ultra Performance Liquid Chromatography-Tandem Mass Spectrometry（UPLC-MS/MS）method was established and validated, the SAMS protein residues in 11 batches of samples were subsequently determined. The results demonstrated that the levels of Saccharomyces cerevisiae host protein and SAMS in the samples were both low, with values below 20 ppm and 1.19 ppm, respectively. The qualitative results also indicate that the types of peptide residues in the samples are more diverse than those of protein residues. Furthermore, residues of proteins and peptides can be detected in all samples, which underscores the importance of evaluating the HCP in API. This study employs a range of complementary detection methods to conduct a comprehensive and sensitive evaluation of total HCP and specific proteins in drugs, thereby guiding more informed assessments of the risks posed by HCP impurities in raw materials during pharmaceutical processes.

Elders' acceptability ratings of behavioral treatments and pharmacotherapy for the management of geriatric behavioral disturbances.

Impurity Profile and Spectrum Characteristics of the Isomers in Cefamandole Nafate Using High- Performance Liquid Chromatography/high-Performance Size Exclusion Chromatography Tandem Ion Trap/time-of-flight Mass Spectrometry

Separation and Characterization of the Polymerized Impurities in Oxacillin Sodium by 2D HPSEC and HPLC IT-TOF MS

Evaluation of Protein Impurities in Ademetionine 1,4-Butanedisulfonate

Impurity profiling of Compound Amino Acid Injection (6AA) using ion-pair high performance liquid chromatography coupled with corona-charged aerosol detection and high resolution mass spectrometry

Development of a rapid reversed-phase liquid chromatographic method for total free thiol quantitation in protein therapeutics

Analysis of Peptides in Plasma by High Performance Liquid Chromatography Coupled with Electrospray Ionization Mass Spectrometry

Characterization of low-level D-amino acid isomeric impurities of Semaglutide using liquid chromatography-high resolution tandem mass spectrometry

Complementary and Alternative Medicine Use by Older Australians

Quantitation of Four Tryptophan-Related Impurities in Compound Amino Acid Injection-18 AA by HPLC–PDA

Identification of lipopeptide isoforms by MALDI-TOF-MS/MS based on the simultaneous purification of iturin, fengycin, and surfactin by RP-HPLC

[Association between cluster of differentiation 14 polymorphism and susceptibility of infection].

Purity determination of synthetic glucagon using a mass balance approach

Simultaneous determination of forsythin and its major metabolites in human plasma via liquid chromatography-tandem mass spectrometry

Identification and Quality Control Strategy of Impurities in Zhengqing Fengtongning Injection

Identification Of Impurities In Lovastatin By High Performance Liquid Chromatography-Diode Array Detection-Mass Spectrometry

Development of a Novel Label-Free Subunit HILIC-MS Method for Domain-Specific Free Thiol Identification and Quantitation in Therapeutic Monoclonal Antibodies

Analysis of impurity profiling of arbekacin sulfate by ion-pair liquid chromatography coupled with pulsed electrochemical detection and online ion suppressor-ion trap-time off light mass spectrometry

Validation of a method for the determination of Aderamastat (FP-025) in K2EDTA human plasma by LC-MS/MS

Improved cell membrane bioaffinity sample pretreatment technique with enhanced stability for screening of potential allergenic components from traditional Chinese medicine injections

Elucidating important factors and corresponding method optimization for sensitive detection of small peptide drugs in human urine by solid‐phase extraction and UPLC‐HRMS: The influence of MS scan modes, protein precipitants, and ammonium formate